SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
The economic burden of supportive care of cancer patients
5 references·2 citing·24 second hop
The economic burden of supportive care of cancer patients (2004)The economic burden of supportive care of…Inflation Spurs Health Spending In 2000 (2002)Inflation Spurs Health Spendi…Evaluating the Total Costs of Chemotherapy-Induced Toxicity: Results from a Pilot Study with Ovarian Cancer Patients (2001)Evaluating the Total Costs of…Current Trends in the Use of Pharmacoeconomics and Outcomes Research in Europe (1999)Current Trends in the Use of …Prevention effectiveness : a guide to decision analysis and economic evaluation (1996)Prevention effectiveness : a …Cost-effectiveness analysis. (1993)Cost-effectiveness analysis.Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer (2016)Cost-effectiveness analysis o…Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis (2012)Ipilimumab in 2nd line treatm…Willingness to Pay for a Quality-adjusted Life Year (2000)What Is the Price of Life and Why Doesn't It Increase at the Rate of Inflation? (2003)Do Oncologists Believe New Cancer Drugs Offer Good Value? (2006)Are The Benefits Of Newer Drugs Worth Their Cost? Evidence From The 1996 MEPS (2001)Comparing Medicare And Private Insurers: Growth Rates In Spending Over Three Decades (2003)Hospital Tiers In Health Insurance: Balancing Consumer Choice With Financial Incentives (2003)Hospitals' Negotiating Leverage with Health Plans: How and Why Has It Changed? (2003)Methods for the economic evaluation of health care programmes (1987)A Cost-Utility Analysis of Second-Line Chemotherapy in Metastatic Breast Cancer (1996)The role of economic evaluation in the pricing and reimbursement of medicines (1997)Economic Evaluations of Healthcare Programmes and Decision Making (2005)Pharmaceutical Pricing Policies in a Global Market (2008)Budget impact analysis in economic evaluation: a proposal for a clearer definition (2011)The Markov Process in Medical Prognosis (1983)Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold (2014)Childhood Abuse, Neglect, and Household Dysfunction and the Risk of Illicit Drug Use: The Adverse Childhood Experiences Study (2003)Economic Costs of Diabetes in the U.S. in 2002 (2003)Adverse childhood experiences and the risk of depressive disorders in adulthood (2004)Recommendations for Reporting Cost-effectiveness Analyses (1996)Trends in Peer Learning (2005)Reprint—Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement (2009)Risk of Incremental Toxicities and Associated Costs of New Anticancer Drugs: A Meta-Analysis (2014)A Systematic Review of the Effect of Cancer Treatment on Work Productivity of Patients and Caregivers (2017)The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC (2017)
this work references cited by second hop

References

  • 1993Cost-effectiveness analysis.816 cited
  • 1996Prevention effectiveness : a guide to decision analysis and economic evaluation576 cited
  • 2001Evaluating the Total Costs of Chemotherapy-Induced Toxicity: Results from a Pilot Study with Ovarian Cancer Patients109 cited
  • 2002Inflation Spurs Health Spending In 2000105 cited
  • 1999Current Trends in the Use of Pharmacoeconomics and Outcomes Research in Europe74 cited

Cited by

  • 2016Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer56 cited
  • 2012Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis51 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work